Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Completed · Phase 1/Phase 2

Conditions studied: Graft Versus Host Disease

In brief

The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment. The study will be separated into two parts; a dose escalation phase to assess safety, followed by a large expansion phase to further evaluate the pharmacologic effects of either a Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include higher risk patients and limit the unrelated donor transplants. After safety is established in part 1 of the study, the second portion of the study will expand the enrollment criteria and allow transplantation by either related or unrelated donors. This study will endeavor to identify the dose range at which RGI-2001 has an acceptable safety profile, at which biologic activity is observed, and to guide possible dose levels to utilize in later phase studies based on biological activity.

Key facts

Study ID

NCT01379209

Run by

Regimmune Corporation

People needed

68

Starts

2011-09-01

Expected to finish

2017-04-01

Last updated by the study team

2019-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has a hematological malignancy or aplastic anemia (AA) and is undergoing a first allogeneic transplant procedure.
• Meet one of the following underlying disease criteria:
• a. Acute myelogenous leukemia (AML) i. First or subsequent morphologic remission b. Acute lymphoblastic leukemia (ALL) i. First or subsequent morphologic remission c. Chronic myelogenous leukemia (CML) i. Chronic phase; or ii. Accelerated phase d. Multiple Myeloma (MM) i. Not more than 20% plasma cells in the bone marrow e. Myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia (CMML), who have received at least one previous induction regimen and have <10% blasts f. Myeloproliferative disorder (MPD), including; i. myeloid metaplasia, and ii. myelofibrosis g. Non-Hodgkin's Lymphoma (NHL) i. High-risk NHL in first remission; or ii. Relapsed or refractory NHL h. Hodgkin's lymphoma (HL) beyond first remission i. Aplastic anemia (AA)
• Male or female, age ≥18 years of age
• Reasonable expectation of survival for at least 3 months, if the transplant procedure is successful
• Eastern Cooperative Oncology Group (ECOG) status of 0-2 or Karnofsky Performance Status (KPS) of > 60
• Transplant Donor
• Part 1 (Phase 1: Dose Escalation Phase):
• Unrelated transplant donor with no more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note: DQ is excluded)
• Part 2 (Phase 2a: Expansion Phase):Related or unrelated transplant donor, with no more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note: DQ is excluded).
• Source of the allograft
• Part 1 (Phase 1: Dose Escalation Phase):Unmodified (non-manipulated) bone marrow, or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the mobilizing agent.
• Part 2: (Phase 2a: Expansion Phase) Unmodified (non-manipulated) bone marrow, or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the mobilizing agent.
• Anti-graft-versus-host disease (GvHD) prophylaxis:
• A calcineurin inhibitor [either tacrolimus (FK506) or cyclosporin A)], in combination with either methotrexate (MTX), mycophenolate mofetil (MMF) or sirolimus (RAPA) all at doses as per the institutional protocols
• Adequate hepatic function, with bilirubin not exceeding the upper limit of normal (except when attributed to Gilbert's Disease), and AST and ALT of less than 1.5 times the upper limit of normal
• No clinically significant cardiac conduction disorder on screening ECG
• Serum creatinine ≤ 2.0 mg/dL
• Female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment and must agree to use dual method of contraception for 30 days after study drug administration. Approved methods of contraception include, an IUD with spermicide, a female condom with spermicide, a diaphragm with spermicide, a cervical cap with spermicide, use of a condom with spermicide by sexual partner or a sterile sexual partner.
• If male, subjects must be sterile or willing to use an approved method of contraception from the time of Informed Consent to 30 days after study drug treatment. Males must be willing to refrain from sperm donation within 30 days after study drug treatment.
• No clinically significant acute or chronic medical condition that in the opinion of the investigator will interfere with study participation
• No clinically significant laboratory abnormalities as determined by the Principal Investigator, in consultation with the Sponsor's Medical Monitor
• No active infection
• Have signed written informed consent before undergoing any study related procedures and is willing to comply with all study procedures

You may not qualify if…

• Female subjects who are pregnant or lactating
• Subjects about to undergo a non-ablative or non-myeloablative transplant
• AML or ALL patient who are in relapse (>5% blasts) or who are defined as primary refractory
• Blast crisis CML
• Radiation, chemotherapy, immunotherapy in the previous 3 weeks, unrelated to the transplant procedure
• Subjects who, in the judgment of the Investigator have not recovered from the effects of previous therapy
• Subject who is about to undergo cord blood transplantation
• Procedures that are intended to deplete regulatory T-cells from donor transplant materials
• Known or suspected HIV infection
• Active hepatitis A, B, or C infection in recipient or donor
• Uncontrolled active infection requiring IV antibiotics in recipient or donor
• Major surgery within 1 month before Day 0
• Participation in an investigational study within 1 month prior to Day 0
• Prior treatment with anti-CD3 antibodies
• Treatment with anti-CD20 antibodies or anti-thymocyte globulin (ATG) within 3 months of the AHSCT procedure (i.e. infusion of transplant material and RGI-2001).
• Vaccination within the preceding 2 weeks prior to the planned dose of RGI-2001
• Planned vaccination within 2 months after study drug administration
• Known history of cardiac dysfunction (e.g. <50% ejection fraction), ischemia, conduction abnormalities, or myocardial infarction in the previous six months
• Cardiac pacemaker or automatic implantable cardioverter-defibrillator
• Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms
• Congenital long QT syndrome or family history of long QT syndrome
• History of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia)
• Bundle branch block
• Connective tissue/rheumatologic disorders
• History of autoimmune disease

Where it is running

• UCSD Moores Cancer Research Institute — San Diego, California, United States
• Stanford School of Medicine — Stanford, California, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Ohio State University Comprehensive Cancer Center - The James — Columbus, Ohio, United States
• Methodist Healthcare System — San Antonio, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.